An International Journal of Otorhinolaryngology Clinics

Register      Login

VOLUME 4 , ISSUE 2 ( May-August, 2012 ) > List of Articles

REVIEW ARTICLE

Current Perspectives in the Pharmacotherapy of Vertigo

Manmohan Singh, Kanchan Rao Singh

Keywords : Pharmacotherapy,Vertigo,Vestibular suppressants

Citation Information : Singh M, Singh KR. Current Perspectives in the Pharmacotherapy of Vertigo. Int J Otorhinolaryngol Clin 2012; 4 (2):81-85.

DOI: 10.5005/jp-journals-10003-1091

Published Online: 00-08-2012

Copyright Statement:  Copyright © 2012; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

How to cite this article

Singh KR, Singh M. Current Perspectives in the Pharmacotherapy of Vertigo. Otorhinolaryngol Clin Int J 2012;4(2):81-85.


PDF Share
  1. In Fauci AS, Kasper DL, Longo DL, Braunwald E, Hauser SL, Jameson JL (Eds). Principles of Internal Medicine. New York, USA: McGraw Hill, 298;144.
  2. Antivertigo medications and drug induced vertigo. Drugs 1995:777–91.
  3. In vitro properties of medial vestibular neurons. In Shimazu H, Shinoda Y (Eds). Vestibular and brainstem control of head and body movement. New York: Karger 1992;111–21.
  4. The effects of N-methyl-D-aspartate antagonists on the development of vestibular compensation in the guinea piga. Eur J Pharmacol 1989;174:273–78.
  5. Double-blind placebo controlled trial with flunarizine in therapy-resistnat epileptic patients. Clin Neuropharmacol 1988;11:232–40.
  6. Muscarinic antagonists in the treatment of acquired pendular and downbeat nystagmus: A double blind randomized trial of three intravenous drugs 1994;35:319–25.
  7. Depression of the vestibule-ocular reflex and optokinetic responses in intrafloccular microinjection of GABA-A and GABA-B agonists in rabbit. Arch Ital Biol 1989;127:243–63.
  8. Neurochemical mechanisms of motion sickness. Am J Otolaryngol 1989;10:351–59.
  9. Dopaminergic agonists have both presynaptic and postsynaptic effects on guinea pig's medial vestibular neurons. Eur J Neurosci 1995;7:555–62.
  10. ACTH(4-10) accelerates ocular motor recovery in guinea pig following vestibular deafferentation. Neurosci Lett 1990;18:14–16.
  11. The treatment of Meniere disease: Torok revisited. Laryngoscope 1991;101:211–18.
  12. Ear Nose Throat J 1996;75:210–14.
  13. An update of pharmacotherapy of vertigo. J Chem Pharm Res 2010;2(3):381–86.
  14. Activation of muscarinic cholinergic receptors inhibits gaint neurons in the caudal pontine reticular nucleus. Eur J Neurosci 2006;24:1967–75.
  15. Meclizine and placebo in treating vertigo of vestibular origin. Relative efficacy a double blind study. Arch Neurol 1972;27:129–35.
  16. Drugs for disturbances in equilibrium. In Modell W, editor. Drugs of choice 1978-79. St Louis (MO): CV Mosby Co., 1978:502–11.
  17. Goodman and Gilman's the pharmacological basis of therapeutics. New York: Pergamon Press, 1990:585.
  18. Current trends of neuro-otological pharmacotherapy for vertigo in germany. Archives of sensology and neurootology in science and practice. XXXV congress of NES; April 2008.
  19. Cinnarizine a labyrinthine sedative. J laryngol Otol 1980;94(9):1009–15.
  20. Orally administered betahistine and regional cerebral blood flow in cerebrovascular disease. J Clin Pharmacol 1974;14:280.
  21. Vertigo and vestibular disorders In: Eadie J, (Ed). Drug therapy in neurology. Edinburgh: Churchill Livingston, 1992:383.
  22. Actions of betahistine at histamine receptors in the brain. Eur J Pharmacol 1985;111:73–84.
  23. Histamine agonists and antagonists. Acta Otolaryngol Suppl 1991;479:5–11.
  24. Histamine and betahistine in the treatment of vertigo: Elucidation of mechanisms of action. CNS Drugs 2001;15:853–70.
  25. Agents affecting gastrointestinal water flux and motility, digestants and bile acids. In: Goodman A, Rall T, Nies A, et al (Eds). Goodman and Gilman's the pharmacological basis of therapeutics. New York: Pergamom Press, 1990:914–32.
  26. Ondensetron. A review of its pharmacology and preliminary clinical findings in novel applications. Drugs 1996;52:773–94.
  27. The systemic application of diazepam facilitates the reaquisition of a well balanced vestibular function in a unilateral vestibular reinput model with intracochlear tetrodotoxin infusion using an osmotic pump. Brain Res 2006;1096:113–19.
  28. Pharmacological treatment of vertigo. CNS Drugs 2003;17:85–100.
  29. Flunarizine: A review of its pharmacodynamic and pharmacokinetics properties and therapeutic use. Drugs 1984;27:6–44.
  30. Calcium antagonists and the vestibular system: A critical review of flunarizine as an antivertigo drug. Fundam Clin Pharmacol 1989;3Suppl:79s–87.
  31. Immunocytochemical detection of vitamin D- dependent calcium-binding protein (Ca BP-28K) in vestibular sensory hair cells and vestibular ganglionic neurons of the cat. Brain Res 1986;364:190–94.
  32. Calcium current in solitary hair cells isolated from frog crista ampullaris. J Vestib Res 1992;2:31–329.
  33. Aviat Space Environ Med 1986;57:45–48.
  34. Postmarketing study of the use of flunarizine in vestibular vertigo and migraine. Eur J Clin Pharmacol 1996;51:15–22.
  35. Nimodipine (Bay e 9736) a new therapy concept in diseases of the inner ear? Laryngol Rhinol Otol (Stuttg) 1985;64:609–13.
  36. Thurtell MJ, Shaikh AG, et al. Pharmacotherapy of vestibular and ocular motor disorders, including nystagmus. J Neurol 2011;258(7):1207–22.
  37. Baclofen and velocity storage: a model of the effects of the drug on the vestibulo-ocular reflex in the Rhesus monkey. J Physiol (London) 1987;393:703–26.
  38. Action de I'acetyl leucine sur le vertigo experimental de la souris. C R Seances Soc Biol Fil 1952;151:1365–67.
  39. Essai de traitement des vertiges labyrinthiqes par I'acetyl-dl-leucine. Therapie 1958;374:274–83.
  40. Strategie, diagnostic et therapeutique devant un sujet attaint de perte soudaine de la function vestibulaire. Cah Otolaryngol 1990;15:569–82.
  41. Treatment of memory impairment, vertigo and tinnitus in the elderly with piribedil in an Indian general practice setting. J Indian Med Assoc 2003;101(8):500–01.
  42. The effectiveness of piracetam in vertigo. Pharmacopsychiatry 1999;32(Suppl 1):54–60.
  43. Ginkgo biloba (EGb 761) in the treatment of equilibrium disorders. Adv Ther 1998;15:291–304.
  44. Behavioral recovery from unilateral lesion is facilitated by GM1 ganglioside treatment. Behav Brain Res 1987;23:117–26.
  45. Trimetazidine versus betahistine in vestibular vertigo. A double blind study. Ann Otolaryngol Chir Cervicofac. 1990;(Suppl 1):11–19.
  46. Trimetazidine versus betahistine in Meniere's disease. A double blind method. Ann Otolaryngol Chir Cervicofac 1990;107(Suppl):20–27.
  47. Phenytoin for motion sickness: Clinical evaluation. Laryngoscope 1994;104:935–39.
  48. Droperidol for the treatment of acute peripheral vertigo. Am J Emerg Med 1999;17(1):109–10.
  49. Observations on pathology of Meniere's syndrome: (Section of otology) Proc R Soc Med 1938;31:317.
  50. Diuretic treatment of Meniere's disease. Long term results with chlorthalidone. Arch Otolaryngol 1074;100:262–65.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.